TB-IRIS Incidence in Disseminated Tuberculosis in Children
The available evidence does not provide specific incidence data for TB-IRIS in children with disseminated tuberculosis, but the limited pediatric literature suggests TB-IRIS occurs in children with HIV-TB coinfection, with disseminated/extrapulmonary TB being a significant risk factor for its development 1, 2.
What We Know About Pediatric TB-IRIS Incidence
The incidence of TB-IRIS in children remains poorly characterized compared to adults. The most comprehensive systematic review identified only 303 pediatric TB-IRIS cases across 13 studies, with the majority (270 cases) being unmasking TB-IRIS rather than paradoxical TB-IRIS 2. This review highlighted a critical gap: none of the cohort studies had TB-IRIS investigation as their primary aim, making true incidence estimates unreliable.
Context from Adult Data
For reference, the STRIDE study in adults reported TB-IRIS occurrence at 7.6%, with 69% of cases being mild to moderate severity 3. However, extrapolating adult incidence rates to children is problematic given the different pathophysiology of tuberculosis in children (paucibacillary primary disease versus adult-type cavitary disease).
Disseminated TB as a Risk Factor
Children with extrapulmonary and disseminated tuberculosis are at significantly higher risk for developing TB-IRIS. In one adult study examining HIV-TB coinfection, extrapulmonary tuberculosis was present in 83.33% of IRIS cases versus 44.87% without IRIS (p = 0.0032), with disseminated tuberculosis specifically associated with IRIS development (33.33%, p = 0.0217) 1.
The systematic review of pediatric TB-IRIS noted that severe presentations were more common in children with extrapulmonary tuberculosis 2, 4. This is particularly relevant for disseminated TB, which represents one of the most severe forms of extrapulmonary disease.
Clinical Implications for Children with Disseminated TB
Key Risk Factors to Monitor:
- Advanced immunosuppression (CD4 counts <50 cells/μL in HIV-infected children) 3, 4
- Early ART initiation (within 2 weeks of starting TB therapy) increases IRIS risk 3, 5
- Disseminated/miliary TB patterns on imaging 3
- Age <4 years with higher risk of dissemination and mortality 3
Timing Considerations:
The median time from cART initiation to IRIS diagnosis in children ranged from 8 days to 16 weeks across studies 2. In adults, IRIS typically occurred after 57 days of ART initiation 1.
Important Caveat - CNS Involvement:
If disseminated TB includes CNS involvement (tuberculous meningitis), delay ART initiation for 8 weeks even with CD4 counts <50 cells/μL, as early ART in CNS TB is associated with increased adverse events and mortality 3. This is a critical exception where IRIS can cause severe or fatal neurological complications.
Recognition and Management
TB-IRIS should be suspected when children on TB treatment develop new or worsening symptoms after immune reconstitution (whether from ART in HIV-infected children or natural immune recovery in HIV-uninfected children) 6. Manifestations include:
- High fevers (most common, 40% of cases) 1
- New or enlarging lymphadenopathy (38% of cases) 1
- Worsening respiratory symptoms
- New radiographic infiltrates or expanding lesions 2, 6
Exclude treatment failure and drug-resistant TB before diagnosing IRIS 3. The diagnosis requires clinical deterioration despite appropriate TB therapy in the context of immune recovery.
Treatment Approach:
- Mild cases: Continue TB and antiretroviral therapy with NSAIDs (ibuprofen) 3
- Moderate to severe cases: Prednisone 1.25 mg/kg/day for 2-4 weeks, then taper over 6-12 weeks 3, 5
- Drainage for significant pleural effusions or abscesses 3
Critical Knowledge Gap
The mortality rate from TB-IRIS in children with disseminated TB is not well-established. Only 6 TB-IRIS-related deaths were reported across the limited pediatric literature 4, and one study found mortality in IRIS cases was not higher than non-IRIS cases 1. However, this likely reflects reporting bias and the paucity of systematic data collection rather than true low mortality, particularly given that disseminated TB itself carries significant mortality risk in young children.
The evidence strongly suggests that prospective studies specifically designed to assess TB-IRIS incidence, risk factors, and outcomes in children with disseminated TB are urgently needed 2, 4, as current management relies heavily on adult data and expert opinion rather than pediatric-specific evidence.